Stockscreener 앱 받기
0.9039
8.24%
-0.0812
시간 외 거래:
.85
-0.0539
-5.96%
전일 마감가:
$0.9851
열려 있는:
$0.97
하루 거래량:
117.84K
Relative Volume:
1.61
시가총액:
$2.62M
수익:
$142.00K
순이익/손실:
$-1.23M
주가수익비율:
1.9409
EPS:
0.4657
순현금흐름:
$-10.62M
1주 성능:
-15.52%
1개월 성능:
-24.67%
6개월 성능:
-59.47%
1년 성능:
-48.93%
1일 변동 폭
$0.8938
$0.99
1주일 범위
$0.8938
$1.0667
52주 변동 폭
$0.8938
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
명칭
Vivosim Labs Inc
전화
858-224-1000
주소
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.9039 | 2.85M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-12-13 | 개시 | H.C. Wainwright | Buy |
| 2017-11-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 개시 | Raymond James | Outperform |
| 2015-08-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 개시 | Jefferies | Buy |
| 2015-06-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Vivosim Labs Inc 주식(VIVS)의 최신 뉴스
VivoSim Labs Delays Annual SEC Filing - TipRanks
VivoSim presents toxicity testing data at European conference By Investing.com - Investing.com South Africa
VivoSim Skids on Data - Baystreet.ca
VivoSim Labs(VIVS) Stock Options Chain | Quotes & News - Moomoo
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting - The Manila Times
VivoSim Presents Data Showing Superiority to Competition in - GlobeNewswire
Enterprise value to revenue forward of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
Price to earnings forward of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
Price to sales forward of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherConsensus Beat Rate - dars.gov.et
VIVS Q3 2025 Earnings: Narrowed Loss Beats Estimates Amid Steady Pipeline ProgressEarnings Beat Alert - dars.gov.et
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates, Revenue UnreportedEstimate Dispersion - newsline.com
VivoSim Labs Faces Pressure: VIVS Stock Falls Over 10% as Key Support ApproachesIchimoku TK Cross - newsline.com
VIVS Q3 2025 Earnings: EPS Surprise of 10.83% Beats Estimates Amid Pre-Revenue PhaseEPS Surprise History - newsline.com
VIVS Q3 2025 Earnings: EPS Surprises to the Upside Amid Operational FocusPretax Income Report - The Legal Advocate
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionNet Profit Margin - newsline.com
VIVS Q3 2025 Earnings: EPS Beat on Cost Management Amidst Ongoing DevelopmentEarnings Analysis - The Legal Advocate
VivoSim Labs VIVS Dips Slightly as Stock Tests Key Support LevelsThe Legal Advocate - The Legal Advocate
VivoSim Labs (VIVS) News Flow - Moomoo
VIVSVivoSim Labs Inc Stock Price and Quote - Finviz
VivoSim Labs Inc. (VIVS) Edges Up 1.49% as It Tests Resistance at $1.43MESA MA - The Legal Advocate
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates Amid Unreported RevenueSocial Signal Watchlist - Newser
VIVS Stock Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VIVS Q4'25 Earnings: EPS estimate is (2.04) USD - TradingView
VIVS Stock Price, Quote & Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VIVS Q4'25 Earnings: revenue estimate is 54.00K USD - TradingView
Number of shareholders of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
Lobbying Update: $10,000 of VIVOSIM LABS INC. lobbying was just disclosed - Quiver Quantitative
VivoSim Labs, Inc. (VIVS) Eps Diluted (TTM) - Zacks Investment Research
What VivoSim Labs (VIVS) capital allocation tells us | Q3 2025: Better Than ExpectedGuidance Update - newser.com
VivoSim Platform Predicts Gastrointestinal Toxicity - GlobeNewswire
VIVS Price Today: VivoSim Labs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
VIVS VivoSim Labs notches 32.1 percent Q3 2025 revenue growth, shares edge higher on narrower than expected loss.AI Stock Signals - Newser
VivoSim Labs (VIVS) Stock: Is It a Compelling Buy (-4.35%) 2026-04-20Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
VIVS Technical Analysis & ETF Price Forecast - Intellectia AI
Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Esousa Group reports 9.9% stake in VivoSim Labs (NASDAQ: VIVS) - Stock Titan
VIVS SEC FilingsVivoSim Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart
VivoSim Labs Prices Best-Efforts Public Offering - TipRanks
VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView
VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan
VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan
VIVS Stock Analysis: VivoSim Labs Inc gains 13.68 percent to 1.62 amid bullish momentum - Newser
VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm
VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia
VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - au.finance.yahoo.com
[EFFECT] VivoSim Labs, INC. SEC Filing - Stock Titan
VivoSim Labs (NASDAQ: VIVS) outlines $4M two-tranche stock and warrant financing - Stock Titan
Aug Breakouts: Is VivoSim Labs Inc benefiting from innovation trendsWeekly Gains Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Vivosim Labs Inc (VIVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):